Injecting INT230-6 then immunochemo before surgery for early TNBC
Part of Cancer, Skin clinical trials.
This trial tests a two-step approach: first, an injection of the drug INT230-6 directly into the breast tumor, followed by a combination of immunotherapy and chemotherapy before surgery. The goal is to see if this sequence can shrink or eliminate the cancer more effectively, potentially allowing for a less extensive surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have early-stage triple-negative breast cancer (stages T1c to T4c, but not the inflammatory type) that has not spread to other organs.
- You must be 18 years or older and in generally good health (able to do most daily activities).
- The main tumor in your breast must be at least 1.5 cm and reachable with a needle for injection.
- You cannot have had any prior chemotherapy, radiation, or targeted therapy for this breast cancer.
- Your blood counts, liver, kidney, and heart function must be within a safe range (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (QL1706) plus chemotherapy given before surgery to shrink early high-risk triple-negative breast cancer. The goal is to see if this treatment can improve the chance of a complete response (no cancer left at surgery).
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether giving a new immunotherapy drug (ivonescimab) together with standard chemotherapy before surgery can help shrink triple-negative breast cancer and improve outcomes.
This trial tests two different sequences of chemotherapy combined with the immunotherapy drug pembrolizumab (Keytruda) before surgery for high-risk triple-negative breast cancer. It aims to see which order works better to shrink tumors and improve outcomes.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.